Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

375
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
375
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

408
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
408
Smooth Endoplasmic Reticulum01:21

Smooth Endoplasmic Reticulum

7.6K
Smooth endoplasmic reticulum or smooth ER is a sub-organelle with specialized functions in animal cells and plant cells. It is often associated with the tubule morphology of the endoplasmic reticulum.
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
7.6K
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

333
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
333
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.0K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.0K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

402
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
402

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glomeruloid haemangioma in Erdheim-Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor-A levels.

British journal of haematology·2026
Same author

Xanthogranulomatous Inflammatory Pelvic Mass Mimicking Malignancy: Successful Conservative Treatment and Narrative Insights into Diagnosis and Management.

Journal of clinical medicine·2026
Same author

Spatial biomarker discovery via interpretable semantic learning in histopathology.

Cancer cell·2026
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Role of the Wnt5A pathway in resistance to immune checkpoint inhibitors in advanced Non-Small Cell Lung Cancer.

Cancer immunology, immunotherapy : CII·2026
Same author

Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.

Oncoimmunology·2026

Related Experiment Video

Updated: Jan 2, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.3K

Erdheim-Chester Disease: a Concise Review.

Matthias Papo1,2, Jean-François Emile3, Thiago Trovati Maciel2

  • 1Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence des Histiocytoses, Hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651, Paris Cedex 13, France.

Current Rheumatology Reports
|December 7, 2019
PubMed
Summary

Erdheim-Chester disease (ECD), a rare histiocytosis, is better understood due to new MAPK pathway mutation discoveries. These findings have led to targeted therapies showing significant effectiveness in clinical trials.

Keywords:
Erdheim-Chester DiseaseHistiocytic NeoplasmHistiocytosisMyeloid NeoplasmTargeted Therapy

More Related Videos

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.7K
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K

Related Experiment Videos

Last Updated: Jan 2, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.3K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.7K
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K

Area of Science:

  • Histiocytosis Research
  • Molecular Pathology
  • Oncology

Background:

  • Erdheim-Chester disease (ECD) is a rare, multi-systemic adult histiocytosis.
  • Understanding ECD pathogenesis has been limited.

Purpose of the Study:

  • To review current knowledge on ECD molecular characterization, clinical description, and treatment.
  • To highlight recent advancements in understanding ECD.

Main Methods:

  • Literature review of molecular characterization studies.
  • Analysis of clinical descriptions and treatment outcomes.
  • Focus on recent genetic discoveries in ECD lesions.

Main Results:

  • Identification of multiple MAPK pathway mutations in ECD histiocytes.
  • BRAFV600E mutation discovery in ECD, alongside other kinase mutations.
  • Targeted therapies based on these mutations have shown robust efficacy.

Conclusions:

  • MAPK pathway mutations are key in ECD pathogenesis.
  • Targeted therapies represent a breakthrough in ECD treatment.
  • Further research into molecular drivers and targeted treatments is warranted.